Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TENX | PRESS-RELEASE | mixed | 7/10 | Tenax Therapeutics announced that its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) in PH-HFpEF missed the primary | Aug 10, 2026 |
| VERU | 8-K | bullish | 7/10 | Veru reported fiscal Q3 2026 results. The net loss per share improved to -$0.30 from -$0.50 a year ago, beating the -$0. | Aug 10, 2026 |
| TEVA | CLUSTER | neutral | 2/10 | Three Teva insiders sold a combined $1.34M in shares over the past week, representing 0.003% of the $41.2B market cap, a | Aug 10, 2026 |
| GLSI | PRESS-RELEASE | bullish | 5/10 | Greenwich LifeSciences extended its insider and pre-IPO investor lock-up to January 31, 2027, preventing share sales dur | Aug 10, 2026 |
| OCS | PRESS-RELEASE | bullish | 5/10 | Oculis entered into an asset purchase agreement to fully acquire Accure Therapeutics' worldwide rights to Privosegtor (A | Aug 10, 2026 |
| VIR | INST-CLUSTER | bullish | 5/10 | Six institutional investors added a net $44.9M to Vir Biotechnology in Q2 2026, led by State Street (+$37.6M) and Pictet | Aug 9, 2026 |
| SVRA | INST-CLUSTER | bullish | 5/10 | Five institutional investors, including Citigroup and Russell Investments Group, significantly increased their positions | Aug 9, 2026 |
| TNGX | INST-CLUSTER | bullish | 6/10 | A strong institutional accumulation cluster for Tango Therapeutics (TNGX) emerged in Q2 2026, with 12 buyers adding a ne | Aug 9, 2026 |
| PVLA | INST-CLUSTER | bullish | 6/10 | 13 institutional buyers accumulated $83.1M in PVLA during Q2 2026, led by Jennison Associates adding $66.9M (50% increas | Aug 9, 2026 |
| NKTR | INST-CLUSTER | bullish | 5/10 | Seven institutional investors accumulated $58.3M in NKTR during Q2 2026, with no sellers. State Street doubled its stake | Aug 9, 2026 |
| ORKA | INST-CLUSTER | bullish | 7/10 | A powerful institutional cluster emerged in Oruka Therapeutics (ORKA) during 2026-Q2, with 19 active asset managers accu | Aug 9, 2026 |
| DFTX | INST-CLUSTER | bullish | 5/10 | A strong institutional cluster emerged in DFTX during Q2 2026, with 10 buyers accumulating $34.3M in net new positions w | Aug 9, 2026 |
| COGT | INST-CLUSTER | bullish | 6/10 | 14 active institutional managers accumulated $112.2M net in COGT during Q2 2026, with zero sellers, a strongly one-sided | Aug 9, 2026 |
| OLMA | INST-CLUSTER | bearish | 6/10 | Institutional cluster for OLMA shows net selling of ~$27.4M in Q2 2026, driven by Jennison Associates' full exit of a $2 | Aug 9, 2026 |
| ELVN | INST-CLUSTER | bullish | 6/10 | Six institutional asset managers accumulated $28.5M in ELVN during Q2 2026, with zero sellers. The largest new position | Aug 9, 2026 |
| ATAI | INST-CLUSTER | bullish | 6/10 | 12 institutional investors accumulated $7.0M in ATAI during Q2 2026, with zero sellers. Bank of New York Mellon ($4.7M) | Aug 9, 2026 |
| JNJ | COURT-RULING | bearish | 4/10 | The Third Circuit reversed the District Court's dismissal of a TCPA class action against J&J subsidiaries, ruling that a | Aug 8, 2026 |
| NKTR | COURT-RULING | neutral | 4/10 | The court issued a pretrial order setting a jury trial for September 8, 2026, in Nektar Therapeutics' patent case agains | Aug 8, 2026 |
| LLY | COURT-RULING | neutral | 3/10 | The court issued a pretrial order in Nektar Therapeutics v. Eli Lilly & Co, setting a jury trial for September 8, 2026, | Aug 8, 2026 |
| MRK | CLUSTER | neutral | 2/10 | Two EVPs at Merck (Williams and Maraldo) executed open-market sales totaling ~$1.4M on August 5, 2026, one day after the | Aug 8, 2026 |
| OKYO | CLUSTER | bullish | 5/10 | Six OKYO Pharma insiders, including the CEO, Chief Development Officer, Chief Scientific Officer, Chief Medical Officer, | Aug 8, 2026 |
| VKTX | CLUSTER | neutral | 4/10 | Three top executives at Viking Therapeutics (CEO, CFO, COO) collectively sold $6.27M in stock on the same day (July 29, | Aug 8, 2026 |
| TWST | CLUSTER | neutral | 4/10 | A cluster of five Twist Bioscience insiders, including the CEO, President/COO, and CAO, sold a total of $2.35M in stock | Aug 8, 2026 |
| MRK | COURT-RULING | bullish | 4/10 | The Third Circuit affirmed the dismissal of Martin & Harris Private Ltd.'s lawsuit against Merck on forum non conveniens | Aug 8, 2026 |
| GEVO | CLUSTER | bearish | 4/10 | Four Gevo insiders, including the CEO and CFO, sold a total of $466K in open-market transactions on the same day (August | Aug 8, 2026 |
| ADMA | INST-CLUSTER | mixed | 4/10 | A mixed institutional cluster in ADMA BIOLOGICS for 2026-Q2 shows 5 buyers accumulating $4.5M in net new positions (led | Aug 8, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP/GC Paul Mahon sold a combined ~$7.5M in open-market shares on August 6, 2026, the day afte | Aug 8, 2026 |
| ATTO | CLUSTER | neutral | 5/10 | No summary provided | Aug 7, 2026 |
| ALKS | CLUSTER | bearish | 4/10 | Three Alkermes insiders, including a director and two EVPs, sold a total of $2.78M in open-market shares on August 3, 20 | Aug 7, 2026 |
| NYMXF | 6-K | neutral | 4/10 | Nymox is calling a special shareholder meeting on August 28, 2026 to elect five directors (versus only two currently ser | Aug 7, 2026 |